日前,美国食品和药物管理局(FDA)批准来那替尼(neratinib)作为早期HER2阳性乳腺癌的扩展辅助治疗药物。来那替尼是此类癌症患者的首个扩展辅助治疗用于既往接受过包括曲妥珠单抗治疗的成人患者初始治疗后进一步降低癌症复发的风险。FDA肿瘤研究中心主管Richard Pazdur说,HER2阳性乳 Recently, the U.S. Food and Drug Administration (FDA) approved neratinib as an extended adjuvant for early-stage HER2-positive breast cancer. Lenalitinib is the first extended adjuvant therapy for patients with such cancers to further reduce the risk of cancer recurrence after initial treatment in adult patients who have previously received treatment with trastuzumab. Richard Pazdur, director of the FDA’s Cancer Research Center, said HER2-positive milk